ClinicalTrials.gg

Program

verekitug

Also written as “Verekitug (UPB-101)”, “Verekitug” and “UPB-101”.

Its studies are mostly in Asthma · Nasal Polyps · Pulmonary Disease, Chronic Obstructive, led by Upstream Bio.

Furthest: phase 2, since Dec 1, 20236 company-led studies, 2 open or runningNext primary completion: Sep 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Upstream Bio62 open or runningphase 2since Dec 1, 2023Jun 29, 2022Sep 2027phase 2 · NCT06966479

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 29, 2022First study: phase 1 study in AsthmaFirst studyNCT05448651 · 32 enrolled · United Kingdom
  2. Dec 7, 2022Phase 1 study in HealthyNCT05653479 · 32 enrolled · United Kingdom
  3. Dec 1, 20232 phase 2 studiesNCT06164704, NCT06196879
  4. May 9, 20252 phase 2 studiesNCT06981078, NCT06966479

Ahead

  1. Sep 2027Primary completion: phase 2 study in AsthmaNCT06966479
  2. Oct 2027Primary completion: phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT06981078

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06981078Pulmonary Disease, Chronic Obstructive · United States, Argentina, Bulgaria and more2Active, not recruitingOct 2027666
NCT06966479Asthma · United States, Argentina, Bulgaria and more2Active, not recruitingSep 2027396
NCT06196879Asthma · United States, Argentina, Bulgaria and more2CompletedDec 16, 2025479
NCT06164704Nasal Polyps · United States, Czechia, Germany and more2CompletedJul 7, 202581
NCT05653479Healthy · United Kingdom1CompletedApr 7, 202332
NCT05448651Asthma · United Kingdom1CompletedAug 15, 202332

How it is read

Names in the registry

  • “Verekitug (UPB-101)”, 2 entries
  • “Verekitug”, 2 entries
  • “UPB-101”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.